Fredun Pharmaceuticals (539730) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, showing continued growth in revenue and profitability year-over-year.

• Board recommended a final dividend of 7% (₹0.70 per share) for FY 2025-26, subject to shareholder approval.

• Issuance of bonus shares in a 2:1 ratio approved, with bonus shares to be issued from reserves and/or share premium.

• Increase in authorized share capital from ₹10 crore to ₹50 crore, pending shareholder approval.

• Appointments of new internal and cost auditors for FY 2026-27 confirmed.

Financial highlights

• Standalone revenue for FY 2025-26 was ₹63,912.17 lakh, up from ₹45,626.82 lakh in FY 2024-25.

• Standalone net profit for FY 2025-26 was ₹3,337.24 lakh, compared to ₹2,046.41 lakh in FY 2024-25.

• Consolidated revenue for FY 2025-26 reached ₹63,912.49 lakh, up from ₹45,626.85 lakh year-over-year.

• Consolidated net profit for FY 2025-26 was ₹3,279.00 lakh, up from ₹1,939.58 lakh in FY 2024-25.

• Basic EPS (standalone) for FY 2025-26 was ₹20.22, up from ₹14.98 in FY 2024-25; consolidated EPS was ₹19.70, up from ₹12.71.

Outlook and guidance

• Board expects continued growth, supported by capital expansion and bonus issue, with dividend payout reflecting confidence in future performance.